Form 8-K - Current report:
SEC Accession No. 0000950170-25-029047
Filing Date
2025-02-27
Accepted
2025-02-27 16:11:30
Documents
13
Period of Report
2025-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vtyx-20250227.htm   iXBRL 8-K 45119
2 EX-99.1 vtyx-ex99_1.htm EX-99.1 151046
3 GRAPHIC img90346216_0.jpg GRAPHIC 43599
  Complete submission text file 0000950170-25-029047.txt   381172

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vtyx-20250227.xsd EX-101.SCH 24847
15 EXTRACTED XBRL INSTANCE DOCUMENT vtyx-20250227_htm.xml XML 4712
Mailing Address 12790 EL CAMINO REAL, SUITE 200 SAN DIEGO CA 92130
Business Address 12790 EL CAMINO REAL, SUITE 200 SAN DIEGO CA 92130 (858) 945-2393
Ventyx Biosciences, Inc. (Filer) CIK: 0001851194 (see all company filings)

EIN.: 832996852 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40928 | Film No.: 25678852
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)